Our favorite day of the year: Give Day. Our flock recently spent the day interacting with staff at a home for elderly residents called De Wingerd where we presented on Flamingo’s innovative #clinicaloncology work, and we learned about their tireless commitment to caring for those with #dementia. We also baked desserts for the staff as a token of appreciation for their work. Finally, our flock finished our day with padel tennis. These moments will inspire us in the months ahead.
About us
Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo Therapeutics has a Phase II trial (PEMDA-HN) evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, funds managed by Tekla Capital Management LLC and VIB.
- Website
-
www.flamingotx.com
External link for Flamingo Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held
Employees at Flamingo Therapeutics
Updates
-
Flamingo Therapeutics reposted this
Looking forward to attending the Mid-Atlantic Capital Conference on October 29 & 30 in Philadelphia, PA and providing a Featured Company Presentation. Thank you Philadelphia Alliance for Capital and Technologies (PACT) for the invitation! Andrew Denker Mark Gidjunis
-
-
Looking forward to attending the Mid-Atlantic Capital Conference on October 29 & 30 in Philadelphia, PA and providing a Featured Company Presentation. Thank you Philadelphia Alliance for Capital and Technologies (PACT) for the invitation! Andrew Denker Mark Gidjunis
-
-
We are proud to sponsor the Head & Neck Cancer Alliance Survivorship Symposium and look forward to engaging with the community at this special event.
-
-
We are attending Chardan's 8th Annual Genetic Medicines Conference in New York Sept. 30-Oct 1. Reach out to schedule time to learn more about Flamingo’s global clinical program for Head and Neck Cancer. Stephane van Rooijen Andrew Denker Mark Gidjunis @clinicaloncology
-
-
At Flamingo, each of us works with passion and purpose. Meet our Flamingo Tiziana Girardi! https://bit.ly/3LjKdKJ
-
-
Flamingo’s VP Finance/Corporate Controller Mark Gidjunis will provide a corporate presentation at the regional Life Sciences Future Conference Sept. 19th at 10:40 am EST. Join us to learn about Flamingo’s growth plan and investment opportunity. https://bit.ly/3z9pshh
-
-
Attending the ESMO - European Society for Medical Oncology? Flamingo CMO Andrew Denker and Director of Development Morgane Perdomini will be there and would love to update you on our ongoing global Phase II study PEMDA-HN for Head and Neck Squamous Cell Carcinoma. Reach out to connect! #clinicaloncology #ESMO24
-
-
Are you attending the Wells Fargo Healthcare Annual Healthcare conference in Boston on Sep 5-6th? Reach out to schedule time with Flamingo CMO Andrew Denker and VP of Finance/Controller Mark Gidjunis.
-
-
Our executive team will be participating in several upcoming investor and industry conferences. Come see us! https://bit.ly/3Xn5859 Stephane van Rooijen Andrew Denker Mark Gidjunis #clinicaloncology
-